Latest Advances from PMV Pharmaceuticals
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP) has revealed promising data from the Phase 2 pivotal segment of the PYNNACLE clinical trial, which investigates rezatapopt for patients with advanced solid tumors associated with the TP53 Y220C mutation.
Efficacy Overview
Significant responses from patients with TP53 Y220C mutated tumors and KRAS wild-type status have been confirmed across eight types of tumors, which include ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinoma.
The overall response rate (ORR) stands at an encouraging 33%. Here’s a breakdown of cohort-specific ORRs:
In the ovarian cancer cohort, a remarkable 43% ORR was observed (19 out of 44 patients), incorporating one confirmed complete response along with 17 confirmed partial responses and one unconfirmed partial response.
For breast cancer, the ORR was 18% (2 out of 11 patients), while endometrial cancer showed a 60% ORR (3 out of 5 patients, which included one unconfirmed partial response). The lung cancer group achieved a 22% ORR (4 out of 18 patients, with three unconfirmed partial responses). Overall, other solid tumors translated into a 21% ORR (4 out of 19 patients).
Across multiple cohorts, the median time to response was 1.4 months, complemented by a median duration of response lasting 6.2 months. Specifically, in the ovarian cohort, the time to response was recorded at 1.3 months, with a median duration of 7.6 months.
Safety Profile of Rezatapopt
Regarding treatment-related adverse events (TRAEs), the majority have been classified as grade 1-2, with the most frequently reported events (occurring in more than 15% of patients) including nausea, fatigue, increased blood creatinine levels, and heightened alanine aminotransferase levels.
Regulatory Insights
In a recent interaction with the U.S. Food and Drug Administration (FDA), PMV Pharmaceuticals has gained insights into the initial strategy for their New Drug Application (NDA) regarding platinum-resistant or refractory ovarian cancer.
The company plans to enroll an additional cohort of 20 to 25 patients suffering from platinum-resistant or refractory ovarian cancer, who have previously undergone standard care, by the conclusion of the first quarter of the following year.
The expectation is to finalize and submit the NDA for this specific indication by the end of the first quarter of the subsequent year.
Current Market Performance: At the latest check, PMVP’s stock has seen a decline of 23.30%, trading at approximately $1.23.
Frequently Asked Questions
What is rezatapopt used for?
Rezatapopt is being studied for its effectiveness in treating advanced solid tumors, particularly those with specific genetic mutations.
What clinical trial is PMV Pharmaceuticals conducting?
PMV Pharmaceuticals is conducting the Phase 2 PYNNACLE clinical trial to evaluate the efficacy of rezatapopt in certain advanced solid tumors.
What has been the response rate observed with rezatapopt?
The overall response rate reported in the trial is 33%, with various response rates depending on the specific tumor type.
What are the common side effects of rezatapopt?
The most common side effects reported by patients include nausea, fatigue, and increases in certain blood parameters.
When does PMV Pharmaceuticals plan to submit the NDA?
PMV Pharmaceuticals aims to submit the New Drug Application for rezatapopt by the end of the first quarter of the upcoming year.
